Literature DB >> 17140547

Lymphangiogenesis and its regulation in human neuroblastoma.

Jeanette Lagodny1, Eva Jüttner, Gian Kayser, Charlotte Marie Niemeyer, Jochen Rössler.   

Abstract

For the first time, we could detect lymph vessels in neuroblastoma (NB) by immunohistochemistry with the antibody D2_40. Furthermore, we demonstrate expression of the lymphangiogenic factors VEGF-C and VEGF-D and their receptors VEGFR-2 and VEGFR-3 in NB in vitro and in vivo by RT-PCR. However, addition of recombinant human VEGF-C or -D results in the absence of autocrine growth stimulus in NB cells. Treatment of NB cells with retinoic acid did not lead to a change in VEGF-C or VEGF-D mRNA expression. Incubation of the NB cells Lan-5 with 5-Aza-2'-deoxycytidine led to the up-regulation of VEGF-C mRNA expression, suggesting that the promotor of VEGF-C is methylated. Finally, VEGF-C mRNA expression could be effectively down-regulated by transfection with a specific siRNA in the NB cells Kelly. We conclude that lymphangiogenesis is involved in NB biology and that siRNA directed against VEGF-C may have a future role in anti-lymphangiogenic strategies in NB.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17140547     DOI: 10.1016/j.bbrc.2006.11.062

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  10 in total

1.  Angiopoietin-2 inhibition using siRNA or the peptide antagonist L1-10 results in antitumor activity in human neuroblastoma.

Authors:  Saritha Sandra D'Souza; Karine Scherzinger-Laude; Marc Simon; Bharathi P Salimath; Jochen Rössler
Journal:  J Cancer Res Clin Oncol       Date:  2012-07-10       Impact factor: 4.553

2.  Neuroblastoma progression correlates with downregulation of the lymphangiogenesis inhibitor sVEGFR-2.

Authors:  Jürgen Becker; Helena Pavlakovic; Fabian Ludewig; Fabiola Wilting; Herbert A Weich; Romulo Albuquerque; Jayakrishna Ambati; Jörg Wilting
Journal:  Clin Cancer Res       Date:  2010-02-23       Impact factor: 12.531

3.  Podoplanin and LYVE-1 expression in lymphatic vessels of human neuroblastoma.

Authors:  Domenico Ribatti; Beatrice Nico; Anca Maria Cimpean; Marius Raica
Journal:  J Neurooncol       Date:  2010-02-27       Impact factor: 4.130

Review 4.  Cell survival signaling in neuroblastoma.

Authors:  Michael L Megison; Lauren A Gillory; Elizabeth A Beierle
Journal:  Anticancer Agents Med Chem       Date:  2013-05       Impact factor: 2.505

5.  PROX1 lymphatic density correlates with adverse clinicopathological factors, lymph node metastases and survival in neuroblastomas.

Authors:  Pramila Ramani; Aimie Norton; Michelle S Somerville; Margaret T May
Journal:  J Neurooncol       Date:  2012-03-01       Impact factor: 4.130

6.  LYVE-1 upregulation and lymphatic invasion correlate with adverse prognostic factors and lymph node metastasis in neuroblastoma.

Authors:  Pramila Ramani; Josiah V Dungwa; Margaret T May
Journal:  Virchows Arch       Date:  2012-01-13       Impact factor: 4.064

Review 7.  Targeting focal adhesion kinase in neuroblastoma.

Authors:  Lauren Gillory; Elizabeth A Beierle
Journal:  Anticancer Agents Med Chem       Date:  2010-12       Impact factor: 2.505

8.  Soluble VEGFR-2: an antilymphangiogenic variant of VEGF receptors.

Authors:  Helena Pavlakovic; Jürgen Becker; Romulo Albuquerque; Jörg Wilting; Jayakrishna Ambati
Journal:  Ann N Y Acad Sci       Date:  2010-10       Impact factor: 5.691

9.  Inhibition of the focal adhesion kinase and vascular endothelial growth factor receptor-3 interaction leads to decreased survival in human neuroblastoma cell lines.

Authors:  Elizabeth A Beierle; Xiaojie Ma; Jerry E Stewart; Michael Megison; William G Cance; Elena V Kurenova
Journal:  Mol Carcinog       Date:  2012-10-12       Impact factor: 4.784

10.  Inhibition of FAK and VEGFR-3 binding decreases tumorigenicity in neuroblastoma.

Authors:  Jerry E Stewart; Xiaojie Ma; Michael Megison; Hugh Nabers; William G Cance; Elena V Kurenova; Elizabeth A Beierle
Journal:  Mol Carcinog       Date:  2013-07-19       Impact factor: 4.784

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.